adamantane and oz 439
adamantane has been researched along with oz 439 in 31 studies
Research
Studies (31)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 26 (83.87) | 24.3611 |
| 2020's | 5 (16.13) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Arbe-Barnes, S; Bathurst, IC; Brun, R; Campbell, M; Charman, SA; Charman, WN; Chiu, FC; Chollet, J; Craft, JC; Creek, DJ; Dong, Y; Matile, H; Maurer, M; Morizzi, J; Nguyen, T; Papastogiannidis, P; Scheurer, C; Shackleford, DM; Sriraghavan, K; Stingelin, L; Tang, Y; Urwyler, H; Vennerstrom, JL; Wang, X; White, KL; Wittlin, S; Zhou, L | 1 |
| Arbe-Barnes, S; Charman, SA; Craft, JC; Duparc, S; Gutierrez, M; Moehrle, JJ; Siethoff, C; van Giersbergen, PL; Vennerstrom, JL; Wittlin, S | 1 |
| Anstey, NM; Chalfein, F; Haynes, RK; Kenangalem, E; Marfurt, J; Möhrle, JJ; Piera, KA; Prayoga, P; Price, RN; Sebayang, B; Wabiser, F; Wirjanata, G; Wittlin, S | 1 |
| Ackerman, HC; Miller, LH; Su, XZ; Wellems, TE | 1 |
| Charman, SA; Chiu, FC; Chollet, J; Dong, Y; Katneni, K; Mannila, J; Morizzi, J; Ryan, E; Santo Tomas, J; Scheurer, C; Snyder, C; Steuten, J; Vennerstrom, JL; Wang, X; Wittlin, S | 1 |
| Blagborough, AM; Brock, PM; Churcher, TS; Delves, MJ; Gething, PW; Ghani, AC; Leroy, D; Sala, KA; Sinden, RE; Upton, LM | 1 |
| Darpo, B; Duparc, S; Ferber, G; Laurijssens, B; Macintyre, F; Siegl, P; Toovey, S | 1 |
| Battilocchio, C; Berry, MB; Galván, A; Lau, SH; Ley, SV; Merchant, RR; Souto, JA | 1 |
| Baker, M; Duparc, S; Imwong, M; Jittamala, P; Macintyre, F; Möhrle, JJ; Nosten, FH; Phyo, AP; Pukrittayakamee, S; White, NJ | 1 |
| Baker, M; Griffin, P; Hooft van Huijsduijnen, R; Marquart, L; McCarthy, JS; Möhrle, JJ; O'Rourke, P | 1 |
| Amante, F; Cooper, MA; Dwyer, PJ; Faleiro, R; Horne-Debets, JM; Huang, JX; Karunarathne, DS; Lee, JS; Leow, CY; McCarthy, JS; Miles, JJ; Poh, CM; Rénia, L; Richard, D; Sharpe, AH; Stacey, KJ; Watkins, TS; Wykes, MN; Yarski, M | 1 |
| Iyengar, K; Roepe, PD; Siriwardana, A | 1 |
| Barker, H; Bulbule, VJ; Charman, SA; Charman, WN; Chiu, FC; Chollet, J; Dhanasekaran, M; Dong, Y; Hein, CD; Kamaraj, S; Matile, H; Morizzi, J; Papastogiannidis, P; Ryan, E; Scheurer, C; Shackleford, DM; Tang, Y; Urwyler, H; Vennerstrom, JL; Wang, X; White, KL; Wittlin, S; Zhao, Q; Zhou, L | 1 |
| Baumgärtner, F; Blasco, B; Campo, B; Jourdan, J; Mäser, P; Scheurer, C; Wittlin, S | 1 |
| Guy, RK; Hammill, JT; Kim, HS | 1 |
| Andenmatten, N; Clark, RL; Clode, SA; Edwards, TL; Huber, AC; Kinney, J; Longo, M; Rhodes, J; Rückle, T; Walker, DK; Wells, T | 1 |
| Charman, SA; Creek, DJ; Giannangelo, C; Stingelin, L; Tilley, L; Yang, T | 1 |
| Adams, M; Bousema, T; Chalon, S; Collins, KA; Elliott, S; McCarthy, JS; Mitchell, H; Möhrle, JJ; Rampton, M; Reuling, IJ; Sauerwein, R; Wang, CY | 1 |
| Boyd, BJ; Clulow, AJ; Gilbert, EP; Hawley, A; Salim, M | 1 |
| Dobrijevic, ELK; Feng, J; Lu, HD; McManus, SA; Mulhearn, WD; Patel, A; Prud'homme, RK; Ramachandruni, H; Ristroph, KD; Zhang, Y | 1 |
| Boyd, BJ; Clulow, AJ; Hawley, A; Khan, J; Ramachandruni, H; Ramirez, G; Salim, M | 1 |
| Beilles, S; Boyd, BJ; Clulow, AJ; Hawley, A; Khan, J; Murshed, M; Ramachandruni, H; Ramirez, G; Salim, M | 1 |
| Feng, J; Gong, K; McManus, SA; Prud'homme, RK; Ramachandruni, H; Ristroph, KD; White, CE; Zhang, Y | 1 |
| Adoke, Y; Barry, A; Dossou, Y; Duong, TT; Khim, N; Klopper, R; Laurijssens, B; Legrand, E; Leroy, D; Macintyre, F; Ménard, D; Mombo-Ngoma, G; Ndong Ngomo, JM; Ouoba, S; Phuc, BQ; Tshefu, AK; Varo, R | 1 |
| Ballard, E; Chalon, S; Collins, KA; Elliott, SL; Griffin, P; Marquart, L; McCarthy, JS; Möhrle, JJ; Rückle, T | 1 |
| Andenmatten, N; Leroy, D; Mäser, P; Walz, A; Wittlin, S | 1 |
| Akakpo, S; Chalon, S; Chughlay, MF; Csermak-Renner, K; Djeriou, E; Gaur, AH; Leboulleux, D; McCarthy, J; Odedra, A; Shanks, GD; Winnips, C | 1 |
| Abd-Rahman, AN; Ballard, E; Chalon, S; Collins, KA; Gobeau, N; Griffin, P; Marquart, L; McCarthy, JS; Möhrle, JJ | 1 |
| Beilles, S; Boyd, BJ; Clulow, AJ; Hawley, A; Peng, KY; Ramachandruni, H; Ramirez, G; Salim, M | 1 |
| Anderson, BM; Charman, SA; Creek, DJ; De Paoli, A; Edgington-Mitchell, LE; Giannangelo, C; Siddiqui, G | 1 |
| Adoke, Y; Bejuit, R; Bohissou, F; Bonzela, JE; Bouyou-Akotet, M; Cantalloube, C; Cherkaoui-Rbati, MH; Duong, TT; Jessel, A; Kaguthi, G; Kibuuka, A; Laurijssens, B; Leroy, D; Macintyre, F; Marrast, AC; Mawili-Mboumba, DP; Mombo-Ngoma, G; Mugenya, I; Nahum, A; Ogutu, B; Olewe, F; Ouattara, D; Ouedraogo, A; Ouoba, S; Phuc, BQ; Soulama, I; Tinto, H; Tiono, AB; Wartha, F; Wells, TNC; White, D; Zoleko-Manego, R | 1 |
Reviews
1 review(s) available for adamantane and oz 439
| Article | Year |
|---|---|
Malaria biology and disease pathogenesis: insights for new treatments.
Topics: Adamantane; Antimalarials; Drug Discovery; Endothelium, Vascular; Erythrocytes; Humans; Malaria; Membrane Transport Proteins; Merozoites; Nitric Oxide; Peroxides; Protein Kinases; Protozoan Proteins | 2013 |
Trials
7 trial(s) available for adamantane and oz 439
| Article | Year |
|---|---|
First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials.
Topics: Adamantane; Administration, Oral; Adolescent; Adult; Antimalarials; Area Under Curve; Chromatography, Liquid; Dose-Response Relationship, Drug; Double-Blind Method; Fasting; Female; Food-Drug Interactions; Half-Life; Humans; Male; Mass Spectrometry; Middle Aged; Peroxides; Young Adult | 2013 |
Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria.
Topics: Adamantane; Adolescent; Adult; Antimalarials; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Healthy Volunteers; Heart Rate; Humans; Long QT Syndrome; Male; Middle Aged; Peroxides; Quinolines; Young Adult | 2015 |
Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial.
Topics: Adamantane; Adolescent; Adult; Antimalarials; Cohort Studies; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Malaria, Falciparum; Malaria, Vivax; Male; Middle Aged; Peroxides; Thailand; Young Adult | 2016 |
A controlled human malaria infection model enabling evaluation of transmission-blocking interventions.
Topics: Adamantane; Adolescent; Adult; Animals; Antimalarials; Culicidae; Erythrocytes; Female; Humans; Malaria, Falciparum; Male; Middle Aged; Models, Biological; Peroxides; Plasmodium falciparum; Primaquine; Quinolines | 2018 |
African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker.
Topics: Adamantane; Adolescent; Adult; Africa; Aged; Antimalarials; Aspartic Acid Endopeptidases; Biomarkers; Child; Child, Preschool; DNA Copy Number Variations; Drug Combinations; Drug Resistance; Female; Genotype; Humans; Infant; Malaria, Falciparum; Male; Middle Aged; Peroxides; Plasmodium falciparum; Protozoan Proteins; Quinolines; Vietnam; Young Adult | 2019 |
A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers.
Topics: Adamantane; Administration, Oral; Adult; Antimalarials; Drug Combinations; Female; Healthy Volunteers; Humans; Malaria, Falciparum; Male; Middle Aged; Parasitemia; Peroxides; Plasmodium falciparum; Pyrimidines; Triazoles; Young Adult | 2019 |
A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria.
Topics: Adamantane; Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Benin; Burkina Faso; Child; Child, Preschool; Double-Blind Method; Drug Combinations; Female; Ferrous Compounds; Gabon; Humans; Infant; Kenya; Malaria, Falciparum; Male; Metallocenes; Middle Aged; Mozambique; Peroxides; Plasmodium falciparum; Uganda; Vietnam; Young Adult | 2021 |
Other Studies
23 other study(ies) available for adamantane and oz 439
| Article | Year |
|---|---|
Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria.
Topics: Adamantane; Animals; Antimalarials; Artemisinins; Dose-Response Relationship, Drug; Drug Stability; Heterocyclic Compounds; Iron; Malaria; Male; Mice; Peroxides; Plasmodium berghei; Rats; Rats, Sprague-Dawley; Time Factors; Treatment Outcome | 2011 |
Comparative ex vivo activity of novel endoperoxides in multidrug-resistant plasmodium falciparum and P. vivax.
Topics: Adamantane; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Chloroquine; Drug Resistance, Multiple; Heterocyclic Compounds, 1-Ring; Microbial Sensitivity Tests; Peroxides; Plasmodium falciparum; Plasmodium vivax; Quinolines; Spiro Compounds | 2012 |
Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.
Topics: Absorption; Adamantane; Animals; Antimalarials; Dioxolanes; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Male; Mice; Peroxides; Plasmodium berghei; Plasmodium falciparum; Spiro Compounds; Structure-Activity Relationship; Tetraoxanes | 2013 |
Lead clinical and preclinical antimalarial drugs can significantly reduce sporozoite transmission to vertebrate populations.
Topics: Adamantane; Animals; Anopheles; Antimalarials; Artemether; Artemisinins; Ethanolamines; Female; Fluorenes; Indoles; Insect Vectors; Lumefantrine; Malaria; Mice; Peroxides; Plasmodium berghei; Primaquine; Spiro Compounds | 2015 |
Machines vs Malaria: A Flow-Based Preparation of the Drug Candidate OZ439.
Topics: Adamantane; Antimalarials; Malaria; Molecular Structure; Peroxides | 2015 |
Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers.
Topics: Adamantane; Administration, Oral; Adolescent; Adult; Antimalarials; Cohort Studies; Female; Healthy Volunteers; Humans; Malaria, Falciparum; Male; Microbial Sensitivity Tests; Parasite Load; Peroxides; Plasmodium falciparum; Real-Time Polymerase Chain Reaction; Treatment Outcome; Young Adult | 2016 |
Programmed Death-1 Ligand 2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing CD4(+) T Cell Immunity.
Topics: Adamantane; Adult; Animals; Antimalarials; B7-H1 Antigen; CD4-Positive T-Lymphocytes; Cells, Cultured; Clinical Trials as Topic; Dendritic Cells; Female; Humans; Immunity, Cellular; Lymphocyte Activation; Malaria, Falciparum; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Parasitemia; Peroxides; Plasmodium falciparum; Programmed Cell Death 1 Ligand 2 Protein; Programmed Cell Death 1 Receptor; Pyrimidines; Triazoles; Young Adult | 2016 |
Endoperoxide Drug Cross-Resistance Patterns for Plasmodium falciparum Exhibiting an Artemisinin Delayed-Clearance Phenotype.
Topics: Adamantane; Antimalarials; Artemether; Artemisinins; Dose-Response Relationship, Drug; Drug Resistance; Heterocyclic Compounds, 1-Ring; Inactivation, Metabolic; Lethal Dose 50; Microbial Sensitivity Tests; Peroxides; Plasmodium falciparum; Spiro Compounds | 2016 |
Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).
Topics: Adamantane; Animals; Antimalarials; Female; Malaria; Male; Mice; Peroxides; Plasmodium berghei; Plasmodium falciparum; Rats; Structure-Activity Relationship | 2017 |
In vitro activity of anti-malarial ozonides against an artemisinin-resistant isolate.
Topics: Adamantane; Antimalarials; Artemisinins; Drug Resistance; Heterocyclic Compounds, 1-Ring; Peroxides; Plasmodium falciparum; Spiro Compounds | 2017 |
Seeking the Elusive Long-Acting Ozonide: Discovery of Artefenomel (OZ439).
Topics: Adamantane; Animals; Antimalarials; Drug Discovery; Humans; Malaria; Peroxides; Plasmodium | 2017 |
Improved safety margin for embryotoxicity in rats for the new endoperoxide artefenomel (OZ439) as compared to artesunate.
Topics: Adamantane; Animals; Antimalarials; Artemisinins; Artesunate; Benzoxazines; Dose-Response Relationship, Drug; Embryo, Mammalian; Female; Fetal Development; Gestational Age; Heme; Organ Culture Techniques; Organogenesis; Peroxides; Phthalimides; Rats | 2018 |
Parasite-Mediated Degradation of Synthetic Ozonide Antimalarials Impacts
Topics: Adamantane; Antimalarials; Erythrocytes; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Peroxides; Plasmodium falciparum; Spiro Compounds; Trophozoites | 2018 |
The Curious Case of the OZ439 Mesylate Salt: An Amphiphilic Antimalarial Drug with Diverse Solution and Solid State Structures.
Topics: Adamantane; Administration, Oral; Antimalarials; Mesylates; Micelles; Peroxides; Scattering, Small Angle; Sodium Chloride; Solubility; Water; X-Ray Diffraction | 2018 |
Encapsulation of OZ439 into Nanoparticles for Supersaturated Drug Release in Oral Malaria Therapy.
Topics: Adamantane; Antimalarials; Drug Compounding; Drug Delivery Systems; Drug Liberation; Humans; Hydrophobic and Hydrophilic Interactions; Ions; Molecular Structure; Nanoparticles; Peroxides | 2018 |
Interactions of Artefenomel (OZ439) with Milk during Digestion: Insights into Digestion-Driven Solubilization and Polymorphic Transformations.
Topics: Adamantane; Administration, Oral; Animals; Antimalarials; Biological Availability; Digestion; Food-Drug Interactions; Lipids; Lipolysis; Milk; Peroxides; Solubility | 2018 |
Impact of Ferroquine on the Solubilization of Artefenomel (OZ439) during in Vitro Lipolysis in Milk and Implications for Oral Combination Therapy for Malaria.
Topics: Adamantane; Administration, Oral; Aminoquinolines; Animals; Antimalarials; Biological Availability; Drug Delivery Systems; Ferrous Compounds; Humans; In Vitro Techniques; Lipolysis; Malaria; Metallocenes; Milk; Peroxides; Solubility | 2019 |
Spray drying OZ439 nanoparticles to form stable, water-dispersible powders for oral malaria therapy.
Topics: Adamantane; Administration, Oral; Chemistry, Pharmaceutical; Desiccation; Drug Stability; Freeze Drying; Humans; Malaria; Nanoparticles; Nebulizers and Vaporizers; Oral Sprays; Peroxides; Powders; Solubility; Water | 2019 |
Anti-malarial ozonides OZ439 and OZ609 tested at clinically relevant compound exposure parameters in a novel ring-stage survival assay.
Topics: Adamantane; Antimalarials; Dose-Response Relationship, Drug; Humans; Malaria, Falciparum; Peroxides; Plasmodium falciparum | 2019 |
Liver Enzyme Elevations in
Topics: Acrylamides; Adamantane; Adult; Alanine Transaminase; Aminopyridines; Aminoquinolines; Antimalarials; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Erythrocyte Transfusion; Erythrocytes; Female; Ferrous Compounds; Healthy Volunteers; Heterocyclic Compounds, 4 or More Rings; Humans; Indoles; Isoquinolines; Malaria, Falciparum; Male; Metallocenes; Parasitemia; Peroxides; Piperazines; Plasmodium falciparum; Primaquine; Pyrimidines; Quinolines; Spiro Compounds; Sulfones; Triazoles; Young Adult | 2020 |
Antimalarial Activity of Artefenomel Against Asexual Parasites and Transmissible Gametocytes During Experimental Blood-Stage Plasmodium vivax Infection.
Topics: Adamantane; Animals; Antimalarials; Culicidae; Folic Acid Antagonists; Humans; Malaria, Falciparum; Malaria, Vivax; Parasites; Peroxides; Plasmodium falciparum; Plasmodium vivax | 2022 |
Lipid Compositions in Infant Formulas Affect the Solubilization of Antimalarial Drugs Artefenomel (OZ439) and Ferroquine during Digestion.
Topics: Adamantane; Administration, Oral; Aminoquinolines; Animals; Antimalarials; Chromatography, High Pressure Liquid; Digestion; Excipients; Fatty Acids; Ferrous Compounds; Humans; Infant; Infant Formula; Lipids; Malaria; Mass Spectrometry; Metallocenes; Milk; Peroxides; Scattering, Small Angle; Solubility; Triglycerides | 2020 |
System-wide biochemical analysis reveals ozonide antimalarials initially act by disrupting Plasmodium falciparum haemoglobin digestion.
Topics: Adamantane; Antimalarials; Erythrocytes; Hemoglobins; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Peroxides; Plasmodium falciparum; Proteomics; Spiro Compounds | 2020 |